- |||||||||| methylprednisolone sodium succinate / Generic mfg.
Journal: Rapidly Progressive Corticobasal Degeneration Mimicking Brainstem Encephalitis. (Pubmed Central) - Feb 24, 2023 The patient did not improve after several cycles of methylprednisolone, intravenous immunoglobulin, and plasma exchange...RP-CBD may resemble brainstem encephalitis. The severity of brainstem and upper spinal cord pathology in the postmortem examination correlated with the clinical and imaging features.
- |||||||||| Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Review, Journal, Adverse events, Checkpoint inhibition: Ocular adverse events associated with immune checkpoint inhibitors, a scoping review. (Pubmed Central) - Feb 22, 2023 Particularly, the difference between actual immune-related adverse events and paraneoplastic syndromes might be relevant. These findings might be of great value in establishing guidelines on how to manage ocular adverse events related to ICIs.
- |||||||||| Hizentra (human immune globulin subcutaneous 20%) / CSL Behring, NN1213 / Novo Nordisk
Trial completion, Trial completion date, Trial primary completion date: A Pilot Trial To Assess The Feasibility And Efficacy Of SCIG In Patients With MG Exacerbation (SCIG-MG) (clinicaltrials.gov) - Feb 21, 2023 P3, N=26, Completed, These findings might be of great value in establishing guidelines on how to manage ocular adverse events related to ICIs. Recruiting --> Completed | Trial completion date: Apr 2024 --> Oct 2022 | Trial primary completion date: Apr 2024 --> Oct 2022
- |||||||||| Journal: Is paravertebral muscles edema a consequence of neurogenic changes in MuSK-positive myasthenia gravis? (Pubmed Central) - Feb 17, 2023
The clinical manifestations, as well as the edematous changes in the paravertebral muscles, regressed after therapy. Thus, these clinical examples may confirm the presence of the neurogenic changes at an early stage of anti-MuSK myasthenia gravis and indicate importance of immediate initiation of therapy to avoid the development of muscle atrophy and fatty infiltration.
- |||||||||| Review, Journal: Inflammation and autoimmune myasthenia gravis. (Pubmed Central) - Feb 17, 2023
A well-designed combination or adjunct treatment utilizing one or more selective and validated promising biomarkers of inflammation as a component of targeted therapy may yield better treatment outcomes. This review briefly discusses some preclinical and clinical findings of inflammation associated with MG and current therapy approaches and suggest the potential of targeting important inflammatory marker(s) along with current monoclonal antibody or antibody fragment based targeted therapies directed to a variety of cell surface receptors.
- |||||||||| docetaxel / Generic mfg.
Biomarker, Journal: Identification of Potential Serum Protein Biomarkers in Thymoma with Myasthenia Gravis After Docetaxel Treatment. (Pubmed Central) - Feb 14, 2023 This review briefly discusses some preclinical and clinical findings of inflammation associated with MG and current therapy approaches and suggest the potential of targeting important inflammatory marker(s) along with current monoclonal antibody or antibody fragment based targeted therapies directed to a variety of cell surface receptors. Our study revealed that the serum proteins were differentially expressed after docetaxel treatment, suggesting their important role in patients with TMG, as well as the critical role of KRAS and SELP as biomarkers in evaluating the efficacy of docetaxel treatment.
- |||||||||| vemircopan (ALXN2050) / AstraZeneca
Trial completion date, Trial primary completion date: ALXN2050-MG-201: Study of ALXN2050 in Adult Participants With Generalized Myasthenia Gravis (clinicaltrials.gov) - Feb 14, 2023 P2, N=70, Recruiting, Our study revealed that the serum proteins were differentially expressed after docetaxel treatment, suggesting their important role in patients with TMG, as well as the critical role of KRAS and SELP as biomarkers in evaluating the efficacy of docetaxel treatment. Trial completion date: Feb 2025 --> Sep 2025 | Trial primary completion date: Feb 2023 --> Jun 2023
- |||||||||| Determination of guanidine in pharmaceutical formulations (Hall F-H (Indiana Convention Center)) - Feb 14, 2023 - Abstract #ACSSp2023ACS_SP_3190;
Trial completion date: Feb 2025 --> Sep 2025 | Trial primary completion date: Feb 2023 --> Jun 2023 The United States Pharmacopeia
- |||||||||| Soliris (eculizumab) / AstraZeneca, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Review, Journal: Ocular Myasthenia Gravis: A Current Overview. (Pubmed Central) - Feb 14, 2023 Reliable and consistent biomarkers are required to assess disease severity and response to therapy to optimize the management of OMG. The purpose of this review is to summarize the current trends and the latest developments in diagnosing and treating OMG.
- |||||||||| Review, Journal: FcRn inhibitors: a novel option for the treatment of myasthenia gravis. (Pubmed Central) - Feb 8, 2023
Antagonizing FcRn to prevent its binding to IgG can accelerate the catabolism of the latter, resulting in decreased levels of IgG, including pathogenic autoantibodies, thereby achieving a therapeutic effect. In this review, we detail the substantial research progress, both basic and clinical, relating to the use of FcRn inhibitors in the treatment of myasthenia gravis.
- |||||||||| Thinking Beyond Hypogammaglobinemia is a Good Strategy in Good Syndrome (Convention Center, Lobby Level, Hall 2) - Feb 4, 2023 - Abstract #AAAAI2023AAAAI_1856;
In patients with thymoma, immunodeficiency evaluation beyond immunoglobulin levels is critical, as multiple patients in this cohort had quantitative and qualitative T cell defects. Autoimmune conditions may predate a Good syndrome diagnosis; notably myasthenia gravis was diagnosed on average 15 years earlier than Good syndrome.
- |||||||||| Review, Journal: A Case of Unicentric Castleman Disease with Concomitant Myasthenia Gravis and Persistent Left Superior Vena Cava. (Pubmed Central) - Feb 3, 2023
Our literature review of all 16 cases of Castleman disease with myasthenia gravis since 1973 revealed that 18.75% of cases were associated with a postoperative myasthenic crisis. This association elicits the importance of prompt diagnosis of myasthenia gravis when evaluating mediastinal masses and the value of having neurology and anesthesiology staff aware of the increased risk of crisis.
- |||||||||| Review, Journal: Myasthenia gravis: Frequently asked questions. (Pubmed Central) - Feb 2, 2023
Treatment is often individualized according to disease severity, antibody status, comorbidities, and other factors. This review uses a question-and-answer format to provide up-to-date, high-yield, clinically relevant information on myasthenia gravis.
- |||||||||| Journal: Myasthenia gravis: An update for internists. (Pubmed Central) - Feb 2, 2023
This review uses a question-and-answer format to provide up-to-date, high-yield, clinically relevant information on myasthenia gravis. No abstract available
- |||||||||| Journal, HEOR: Healthcare resource use in myasthenia gravis: a US health claims analysis. (Pubmed Central) - Jan 31, 2023
Patients with MG have higher HCRU, compared with the age- and sex-matched non-MG controls. The early years after MG diagnosis are a period of particularly high healthcare burden, with many patients requiring hospitalization and ICU care to manage serious exacerbations.
|